<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000337</url>
  </required_header>
  <id_info>
    <org_study_id>Î£-74/07-07-2009</org_study_id>
    <nct_id>NCT01000337</nct_id>
  </id_info>
  <brief_title>Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol</brief_title>
  <official_title>The Impact of Sevoflurane and Propofol Anesthesia on Hepatic Apoptosis Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anesthesia may affect the function of vital organs. Liver is one of them. The investigator's
      hypothesis is that intravenous or inhalation anesthesia does not impair liver function as
      assessed by more elegant tests like markers indicating liver apoptosis. In the present
      randomized prospective trial female patients scheduled for mastectomy or thyroidectomy will
      receive inhalation or total intravenous anesthesia and markers for liver dysfunction will be
      determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female patients undergoing mastectomy or thyroidectomy under sevoflurane or propofol
      anesthesia will be recruited for the study. The type of anesthesia will be determined in a
      random way using a computer generated table.

      All patients will be preoxygenated for 3 minutes before induction of anesthesia. Patients
      assigned to the sevoflurane group will receive an inhalation induction with sevoflurane via a
      primed anesthetic circle system and anesthesia will be maintained with sevoflurane. In the
      propofol group patients anaesthesia will be induced and maintained with propofol.

      Blood samples for liver apoptotic markers will be collected before induction of anesthesia,
      after skin closure as well as 24 and 48 hours postoperatively.

      Blood samples will be centrifuged, stored at -80 degrees Celsius and analyzed for M30 and M60
      values with radioimmunoassay technique. Serum glutamic pyruvic transaminase (SGPT) and serum
      glutamic oxaloacetic transaminase (SGOT) levels will also be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the M30 and M65 Markers Related to the Anesthesia Type</measure>
    <time_frame>preoperatively, end of surgery, 24 and 48 hours postoperatively</time_frame>
    <description>Blood samples for determination of the markers M30 and M65 as well as the serum transaminases were collected preoperatively, at the end of surgery, 24 and 48 hours postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transaminases</measure>
    <time_frame>February 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volatile anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.</description>
    <arm_group_label>sevoflurane</arm_group_label>
    <other_name>Sevorane, 2802252901023,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Lipuro, 2802467102017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged between 30 and 65 years old scheduled for thyroidectomy or breast
             surgery for cancer

        Exclusion Criteria:

          -  Drug intake which may affect liver function

          -  Severe cardiovascular or respiratory disease

          -  Hepatic or renal dysfunction

          -  Pregnancy

          -  Alcohol and drug abuse

          -  Body Mass Index (BMI) &gt; 35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Argyro Fassoulaki, MD,PhD,DEAA</last_name>
    <role>Study Chair</role>
    <affiliation>Chairman Department of Anesthesiology, Aretaieio Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aretaieio Hospital, University of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <results_first_submitted>May 7, 2012</results_first_submitted>
  <results_first_submitted_qc>August 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2012</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Argyro Fassoulaki</investigator_full_name>
    <investigator_title>MD, PhD, DEAA</investigator_title>
  </responsible_party>
  <keyword>Liver Apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between October 2009 and July 2011 in Aretaieo University Hospital, Athens, Greece</recruitment_details>
      <pre_assignment_details>Potential participants prior to group assignment were enrolled but excluded from the trial due to exclusion criteria as defined by the study protocol</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevoflurane</title>
          <description>Volatile anesthetic used to induce and maintain general anaeshesia. To induce anaesthesia the inspired concentration recommended is 8% in oxyfen to maintain anaesthesia the inspired concentration is 1-2%. The drug is administered continuously during surgery using a specially designed vaporizer. The depth of anesthesia obtained during sevoflurane administration is monitored by the end expired concentration of sevoflurane and by the bispectral index monitoring. The effect of sevoflurane on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Intravenous anesthetic suitable for induction and maintainance of general anesthesia. Anaesthesia is induced by administereing intravenously 2-2.5 mg/kg body weight and maintained by continuous intravenous infusion of 6 mg/kg/hour of propofol by means of an electric infusion pump.
The depth of anesthesia during propofol anesthesia is monitored by the bispectral index monitoring. The effect of propofol on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sevoflurane</title>
          <description>Volatile anesthetic used to induce and maintain general anaeshesia. To induce anaesthesia the inspired concentration recommended is 8% in oxyfen to maintain anaesthesia the inspired concentration is 1-2%. The drug is administered continuously during surgery using a specially designed vaporizer. The depth of anesthesia obtained during sevoflurane administration is monitored by the end expired concentration of sevoflurane and by the bispectral index monitoring. The effect of sevoflurane on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Intravenous anesthetic suitable for induction and maintainance of general anesthesia. Anaesthesia is induced by administereing intravenously 2-2.5 mg/kg body weight and maintained by continuous intravenous infusion of 6 mg/kg/hour of propofol by means of an electric infusion pump.
The depth of anesthesia during propofol anesthesia is monitored by the bispectral index monitoring. The effect of propofol on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.93" spread="10.19"/>
                    <measurement group_id="B2" value="48.30" spread="10.81"/>
                    <measurement group_id="B3" value="51.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the M30 and M65 Markers Related to the Anesthesia Type</title>
        <description>Blood samples for determination of the markers M30 and M65 as well as the serum transaminases were collected preoperatively, at the end of surgery, 24 and 48 hours postoperatively.</description>
        <time_frame>preoperatively, end of surgery, 24 and 48 hours postoperatively</time_frame>
        <population>For an effect size of 0.20 assuming a two-sided error type I error of 0.05 and a power of 0.80, a sample size of 60 sixty patients (30 patients in each group) would be required.</population>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Volatile anesthetic used to induce and maintain general anaeshesia. To induce anaesthesia the inspired concentration recommended is 8% in oxyfen to maintain anaesthesia the inspired concentration is 1-2%. The drug is administered continuously during surgery using a specially designed vaporizer. The depth of anesthesia obtained during sevoflurane administration is monitored by the end expired concentration of sevoflurane and by the bispectral index monitoring. The effect of sevoflurane on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Intravenous anesthetic suitable for induction and maintainance of general anesthesia. Anaesthesia is induced by administereing intravenously 2-2.5 mg/kg body weight and maintained by continuous intravenous infusion of 6 mg/kg/hour of propofol by means of an electric infusion pump.
The depth of anesthesia during propofol anesthesia is monitored by the bispectral index monitoring. The effect of propofol on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the M30 and M65 Markers Related to the Anesthesia Type</title>
          <description>Blood samples for determination of the markers M30 and M65 as well as the serum transaminases were collected preoperatively, at the end of surgery, 24 and 48 hours postoperatively.</description>
          <population>For an effect size of 0.20 assuming a two-sided error type I error of 0.05 and a power of 0.80, a sample size of 60 sixty patients (30 patients in each group) would be required.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M30 marker preoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.27" spread="95.46"/>
                    <measurement group_id="O2" value="279.97" spread="228.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M65 marker preoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427.33" spread="225.70"/>
                    <measurement group_id="O2" value="470.30" spread="261.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M30 marker postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.83" spread="108.60"/>
                    <measurement group_id="O2" value="299.97" spread="243.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M65 marker postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480.90" spread="227.51"/>
                    <measurement group_id="O2" value="478.27" spread="271.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M30 marker 24h postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.10" spread="93.67"/>
                    <measurement group_id="O2" value="267.17" spread="197.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M65 marker 24h postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.17" spread="158.12"/>
                    <measurement group_id="O2" value="456.43" spread="338.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M30 marker 48h postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.10" spread="127.27"/>
                    <measurement group_id="O2" value="254.20" spread="188.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M65 marker 48h postoperatively</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.20" spread="144.01"/>
                    <measurement group_id="O2" value="485.53" spread="272.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transaminases</title>
        <time_frame>February 2011</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the first 48 hours after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sevoflurane</title>
          <description>Volatile anesthetic used to induce and maintain general anaeshesia. To induce anaesthesia the inspired concentration recommended is 8% in oxyfen to maintain anaesthesia the inspired concentration is 1-2%. The drug is administered continuously during surgery using a specially designed vaporizer. The depth of anesthesia obtained during sevoflurane administration is monitored by the end expired concentration of sevoflurane and by the bispectral index monitoring. The effect of sevoflurane on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Intravenous anesthetic suitable for induction and maintainance of general anesthesia. Anaesthesia is induced by administereing intravenously 2-2.5 mg/kg body weight and maintained by continuous intravenous infusion of 6 mg/kg/hour of propofol by means of an electric infusion pump.
The depth of anesthesia during propofol anesthesia is monitored by the bispectral index monitoring. The effect of propofol on the liver for the predetermined clinically applicable concentrations was evaluated.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was accomplished with no problems leading to data questioning.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Argyro Fassoulaki</name_or_title>
      <organization>Aretaieio Hospital, University of Athens</organization>
      <phone>+30210 7286334</phone>
      <email>fassoula@aretaieio.uoa.gr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

